Skip to Main Content
HBS Home
  • About
  • Academic Programs
  • Alumni
  • Faculty & Research
  • Baker Library
  • Giving
  • Harvard Business Review
  • Initiatives
  • News
  • Recruit
  • Map / Directions
Faculty & Research
  • Faculty
  • Research
  • Featured Topics
  • Academic Units
  • …→
  • Harvard Business School→
  • Faculty & Research→
  • Research
    • Research
    • Publications
    • Global Research Centers
    • Case Development
    • Initiatives & Projects
    • Research Services
    • Seminars & Conferences
    →
  • Publications→

Publications

Publications

Filter Results: (1,244) Arrow Down
Filter Results: (1,244) Arrow Down Arrow Up

Show Results For

  • All HBS Web  (1,244)
    • People  (5)
    • News  (171)
    • Research  (928)
    • Events  (6)
    • Multimedia  (12)
  • Faculty Publications  (756)

Show Results For

  • All HBS Web  (1,244)
    • People  (5)
    • News  (171)
    • Research  (928)
    • Events  (6)
    • Multimedia  (12)
  • Faculty Publications  (756)
← Page 24 of 1,244 Results →

    Gary P. Pisano

    Gary Pisano is the Harry E. Figgie, Jr. Professor of Business Administration at the Harvard Business School where he has been on the faculty since 1988. From 2018-2023, Pisano was Harvard Business School’s Senior Associate Dean for Faculty Promotion and... View Details

    Keywords: pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals

      Nitin Nohria

      Nitin Nohria served as the tenth dean of Harvard Business School from 2010-2020. He previously served as co-chair of the Leadership Initiative, Senior Associate Dean of Faculty Development, and Head of the Organizational Behavior unit.

      As Dean, building on... View Details

      Keywords: pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals
      • Web

      Employment Data Trends

      Employment Data Trends Employment Data Trends Trends Career Data Internship Data Trends by Industry 2020 2021 2022 2023 2024 Consulting 24% 23% 26% 25% 18% Consumer Products 3% 3% 3% 4% 3% Entertainment / Media 2% 3% 3% 1% 3% Health Care 7% 6% 5% 5% 6% Biomed / View Details
      • Web

      All Industries

      Entertainment / Media 3% $150k 25th Percentile Base $165k Median $184k 75th Percentile Base $13k 40% Receiving $21k 60% Receiving Health Care 6% + – Expand Row $145k 25th Percentile Base $165k Median $185k 75th Percentile Base $30k 66% Receiving $29k 71% Receiving... View Details
      • 18 Apr 2023
      • Research & Ideas

      The Best Person to Lead Your Company Doesn't Work There—Yet

      within their own ranks. “What you really do need is knowledge of that specific industry, whether it's pharmaceutical or manufacturing or hospitality or rocket science.” The findings suggest an active market for CEOs, who are lured to... View Details
      Keywords: by Rachel Layne; Financial Services

        Rosabeth M. Kanter

        Rosabeth Moss Kanter holds the Ernest L. Arbuckle Professorship at Harvard Business School, specializing in strategy, innovation, and leadership for change. Her strategic and practical insights guide leaders worldwide through teaching, writing, and direct... View Details

        Keywords: pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals

          Youngme Moon

          Youngme Moon is the Donald K. David Professor of Business at Harvard Business School. Professor Moon's research sits at the intersection of brand strategy and culture, with a particular focus on the emergent AI economy. She is the author of the bestselling book, View Details

          Keywords: pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals
          • 15 Jan 2019
          • First Look

          New Research and Ideas, January 15, 2019

          December 19, 2018 NEJM Catalyst It's Time to Reform the Orphan Drug Act By: Bagley, Nicholas, Amitabh Chandra, Craig Garthwaite, and Ariel Dora Stern Abstract—No abstract available. Publisher's link: https://www.hbs.edu/faculty/Pages/item.aspx?num=55448 January 2019... View Details
          Keywords: Dina Gerdeman
          • January–February 2023
          • Article

          Forecasting COVID-19 and Analyzing the Effect of Government Interventions

          By: Michael Lingzhi Li, Hamza Tazi Bouardi, Omar Skali Lami, Thomas Trikalinos, Nikolaos Trichakis and Dimitris Bertsimas
          We developed DELPHI, a novel epidemiological model for predicting detected cases and deaths in the prevaccination era of the COVID-19 pandemic. The model allows for underdetection of infections and effects of government interventions. We have applied DELPHI across more... View Details
          Keywords: COVID-19 Pandemic; Epidemics; Analytics and Data Science; Health Pandemics; AI and Machine Learning; Forecasting and Prediction
          Citation
          Read Now
          Related
          Li, Michael Lingzhi, Hamza Tazi Bouardi, Omar Skali Lami, Thomas Trikalinos, Nikolaos Trichakis, and Dimitris Bertsimas. "Forecasting COVID-19 and Analyzing the Effect of Government Interventions." Operations Research 71, no. 1 (January–February 2023): 184–201.

            Kyle R. Myers

            Kyle Myers is an assistant professor of business administration in the Technology and Operations Management unit. He teaches the first-year Technology and Operations Management course.

            Professor Myers studies the economics of innovation. His research is at... View Details

            Keywords: pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals
            • Research Summary

            Regulatory Change/Business-Government Relations

            “Sources of Learning Heterogeneity: Discontinuous Regulatory Shock and its Impact on Organizational Search Behaviors”

            Co-authoring with Jerry Kim, in this study I look at how discontinuous regulatory shock shapes organizational... View Details

            Keywords: Business & Government Relations; Regulations; Regulatory Capture; Pharmaceutical Industry; United States
            • Research Summary

            Clinical Trials as a setting for Health Policy and Management Research

            The clinical trial marketplace is in flux. A decade ago, pharmaceutical firms almost exclusively conducted the study of their novel drug compounds within major academic medical centers. But today, industry-sponsored clinical trials are increasingly using community... View Details
            • Web

            HBS - The year in Review

            standards, and values of the School. The recipients were honored during the Class Day ceremony. The 2023 Award recipients were Reshma Kewalramani MD, FASN (GMP 18, 2015) CEO and President, Vertex Pharmaceuticals Depelsha Thomas McGruder... View Details
            • 04 Jun 2013
            • Working Paper Summaries

            Prosocial Bonuses Increase Employee Satisfaction and Team Performance

            Keywords: by Lalin Anik, Lara B. Aknin, Michael I. Norton, Elizabeth W. Dunn & Jordi Quoidbach

              Stefan H. Thomke

              Stefan Thomke (sthomke@hbs.edu), an authority on the management of innovation, is the William Barclay Harding Professor of Business Administration at Harvard Business School. He has worked with firms on product, process, and... View Details

              Keywords: pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals; pharmaceuticals
              • October 1982 (Revised May 1992)
              • Case

              Johnson & Johnson: The Tylenol Tragedy

              By: Stephen A. Greyser
              In October 1982, Johnson & Johnson was confronted with a major crisis when seven deaths were attributed to poisoned Tylenol. The case reviews the facts as known a week after the incident occurred, and raises a wide range of questions regarding consumer behavior,... View Details
              Keywords: Consumer Behavior; Corporate Social Responsibility and Impact; Competitive Strategy; Crisis Management; Health Care and Treatment; Pharmaceutical Industry
              Citation
              Educators
              Purchase
              Related
              Greyser, Stephen A. "Johnson & Johnson: The Tylenol Tragedy." Harvard Business School Case 583-043, October 1982. (Revised May 1992.)
              • Forthcoming
              • Article

              Achieving Epilepsy Care for All: Ecosystem-Based Transformation

              By: Susanna Gallani, Bernice Martin Lee and Lidia M. V. R. Moura
              Epilepsy exemplifies many of the systemic challenges of modern health care— fragmented care delivery, inequitable access, financial strain, and so on. The current “system of systems” (SoS) structure of U.S. health care fosters siloed operations among its member systems... View Details
              Keywords: Healthcare Delivery; Epilepsy; Seizures; Health Care and Treatment; Health Disorders; Equality and Inequality; Framework; Service Delivery
              Citation
              Find at Harvard
              Read Now
              Purchase
              Related
              Gallani, Susanna, Bernice Martin Lee, and Lidia M. V. R. Moura. "Achieving Epilepsy Care for All: Ecosystem-Based Transformation." Epilepsia (forthcoming). (Pre-published online April 4, 2025.)
              • 07 Jan 2010
              • Working Paper Summaries

              International Differences in the Size and Roles of Corporate Headquarters: An Empirical Examination

              Keywords: by David Collis, David Young & Michael Goold
              • Research Summary

              Putting Patients First: Marketing Strategies for Treating HIV in Developing Nations

              It is more than mere coincidence that the highest rates of HIV occur in the world’s poorest countries. Of the over 40 million people currently living with HIV, 95 percent are in the developing world. The first half of this paper explores the economics of HIV and... View Details
              • November–December 2015
              • Article

              Active Postmarketing Drug Surveillance for Multiple Adverse Events

              By: Joel Goh, Margrét V. Bjarnadóttir, Mohsen Bayati and Stefanos A. Zenios
              Postmarketing drug surveillance is the process of monitoring the adverse events of pharmaceutical or medical devices after they are approved by the appropriate regulatory authorities. Historically, such surveillance was based on voluntary reports by medical... View Details
              Keywords: Drug Surveillance; Health Care; Stochastic Models; Queueing; Diffusion Approximation; Brownian Motion; Health Care and Treatment; Analytics and Data Science; Analysis
              Citation
              Find at Harvard
              Related
              Goh, Joel, Margrét V. Bjarnadóttir, Mohsen Bayati, and Stefanos A. Zenios. "Active Postmarketing Drug Surveillance for Multiple Adverse Events." Operations Research 63, no. 6 (November–December 2015): 1528–1546. (Finalist, 2012 INFORMS Health Applications Society Pierskalla Award.)
              • ←
              • 24
              • 25
              • …
              • 62
              • 63
              • →
              ǁ
              Campus Map
              Harvard Business School
              Soldiers Field
              Boston, MA 02163
              →Map & Directions
              →More Contact Information
              • Make a Gift
              • Site Map
              • Jobs
              • Harvard University
              • Trademarks
              • Policies
              • Accessibility
              • Digital Accessibility
              Copyright © President & Fellows of Harvard College.